Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis
Brief Summary: Tuberculosis is currently treated with a 6-month course regimen. During this time many patients might fail to adhere to treatment and default, increasing the risk of recurrent disease which might be multidrug resistant. A shorter duration of treatment is expected to provide improved patient compliance and at least equal or better clinical outcome. The aim of the trial is to evaluate the efficacy and safety of a gatifloxacin-containing regimen of four months duration for the treatment of pulmonary tuberculosis,


Options:
A: Arm Label: TMC207 Stage 1; Type: EXPERIMENTAL; Interventions: Drug: TMC207, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: Placebo Stage 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: TMC207 Stage 2; Type: EXPERIMENTAL; Interventions: Drug: TMC207, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: Placebo Stage 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Intervention Type: DRUG; Name: TMC207; Assigned to Arm(s): TMC207 Stage 1, TMC207 Stage 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Stage 1, Placebo Stage 2 | Intervention Type: DRUG; Name: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis); Assigned to Arm(s): Placebo Stage 1, Placebo Stage 2, TMC207 Stage 1, TMC207 Stage 2
B: Intervention Type: DRUG; Name: Gatifloxacin combined regimen; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Moxifloxacin | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): 1, 2
D: Arm Label: TMC207; Type: EXPERIMENTAL; Interventions: Drug: TMC207 | Arm Label: TMC207 and pyrazinamide; Type: EXPERIMENTAL; Interventions: Drug: Pyrazinamide, Drug: TMC207 | Arm Label: PA-824 and pyrazinamide; Type: EXPERIMENTAL; Interventions: Drug: PA-824, Drug: Pyrazinamide | Arm Label: PA-824 and moxifloxacin and pyrazinamide; Type: EXPERIMENTAL; Interventions: Drug: PA-824, Drug: Moxifloxacin | Arm Label: Rifafour e-275 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rifafour | Arm Label: TMC207 and PA-824; Type: EXPERIMENTAL; Interventions: Drug: PA-824, Drug: TMC207 | Intervention Type: DRUG; Name: PA-824; Assigned to Arm(s): PA-824 and moxifloxacin and pyrazinamide, PA-824 and pyrazinamide, TMC207 and PA-824 | Intervention Type: DRUG; Name: Pyrazinamide; Assigned to Arm(s): PA-824 and pyrazinamide, TMC207 and pyrazinamide | Intervention Type: DRUG; Name: TMC207; Assigned to Arm(s): TMC207, TMC207 and PA-824, TMC207 and pyrazinamide | Intervention Type: DRUG; Name: Rifafour; Assigned to Arm(s): Rifafour e-275 mg | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): PA-824 and moxifloxacin and pyrazinamide

Answer: B